HGG-38. A COMPARATIVE PROTEOMIC-ANALYSIS OF THE CELL MEMBRANE FRACTIONS OF HISTONE 3 MUTATED BRAIN TUMOURS TO IDENTIFY NOVEL THERAPEUTICS. (4th December 2020)

• Record Type: Journal Article
• Authors: Pickering, James; Rahman, Ruman; Grundy, Richard; Layfield, Robert; Haque, Farhana
• Is Part Of: Neuro-oncology. Volume 22(2020)Supplement 3
• Page Start: iii350
• Page End: iii350
• Publication Date: 2020-12-04
• Subjects: Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noaa222.319
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Improvements in the treatments for childhood and adolescent brain tumours, High-Grade Glioma (pHGG) and Diffuse Intrinsic Pontine Glioblastoma (DIPG), have not advanced much and they continue to carry a very poor prognosis. These brain tumours are now defined by mutations affecting histone 3 proteins, indeed 80% of DIPGs harbour histone H3.1 and H3.3 K27M somatic mutations whilst 30% of pHGGs exhibit H3.3 G34R or G34V mutations. We hypothesized that the histone 3 mutant tumours will have distinct mutation specific surfactome. We therefore analysed the cell surface proteomics of pHGG and DIPG, in order to identify novel targets for therapy. We have at first isolated the cell membrane fractions from a range of patient cells carrying different histone 3 mutations (G34R, G34V, K27M), relative to wild type histone 3. A comparative quantitative mass-spectrometry analyses of these cell surface membrane fractions is then performed to identify specific targetable factors, which can be then be used for tumour specific precision-therapy. Results of these experiments will be presented.